Syngenta has announced its full-year financial results for 2025, showcasing biologicals as a prominent growth segment despite a slight dip in overall sales year-over-year. The agricultural giant has remained tight-lipped on the possibility of an IPO, amidst ongoing speculation.

The crop protection and seed company reported a total revenue of $28.4 billion for FY 2025, ending December 31, which reflects a 1% decline compared to the previous year. However, the fourth quarter exhibited a positive trend, with sales increasing by 2% to $7.6 billion.

Growth in Biologicals

Within Syngenta’s business segments, biologicals emerged as a significant area of growth. Daniele Nocera, group treasurer at Syngenta, stated during an investor presentation that the biologicals segment achieved an impressive double-digit growth of 11%, showcasing strong demand across virtually all regions except for Mexico.

Research and development sustained focus as a pivotal element for Syngenta’s growth, with approximately 7% of its revenue allocated to R&D. Nocera highlighted that they registered nearly 1,800 new products, featuring key active ingredients like Plinazolin, Adepidyn, and Tymirium, which are expected to contribute to volume growth.

The Brazilian market saw the launch of the nematode protection product Tymirium in Q4 2025, despite facing a challenging year marked by rising generic competition and difficult farmer profitability, as noted by Nocera.

Speculations Around an IPO

During the financial call, discussions around the possibility of an IPO arose, especially given Syngenta’s acquisition by ChemChina in May 2017 and subsequent delisting from the SIX Swiss Exchange. Reports suggest that Syngenta may consider a $10 billion IPO on the Hong Kong Stock Exchange in the second quarter of 2026, as per Reuters.

Nocera mentioned, “Syngenta Group continues to see an IPO as a strategic option to facilitate growth while monitoring market conditions.” He stressed, however, that no definitive decisions have been made at this point.

Analyzing FY 2025 Results

Syngenta reported sales growth in both its crop protection and seed sectors, amassing $13.7 billion and $4.8 billion in sales, respectively. The crop protection sector saw a 4% rise, while seeds grew by 2% year-over-year.

In North America, Syngenta enjoyed a 10% increase in sales within crop protection. Meanwhile, Europe and the Asia, Middle East, and Africa (AMEA) regions, excluding China, reported a growth of 5%. Conversely, Brazil’s sales dipped slightly by 1%, and the broader Latin America experienced a 3% decline.

In the seeds sector, Brazil, Latin America, and China saw substantial growth, with increases of 17%, 10%, and 6%, respectively. However, the North American seed sales took a hit, down by 12%, largely due to restructuring, while AMEA fell by 1%.

Future Outlook

Looking ahead, Syngenta is setting ambitious targets, aiming for a 20% EBITDA margin by the end of the year, while navigating challenging macroeconomic conditions, such as the ongoing geopolitical tensions resulting from the conflict in Iran, which are projected to elevate raw material and energy costs.

Nocera concluded, “Geopolitical tensions create market uncertainties. Although global crop protection and seed markets are stabilizing, we expect grower profitability to remain strained, with no significant economic improvements in the near future.”